Inventor
VELAPARTHI UPENDER
US33 patents
⚠️ This page may combine multiple inventors who share the name “VELAPARTHI UPENDER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
22 patentsUS7534792B2May 19, 2009
Pyrrolotriazine kinase inhibitors
BRISTOL MYERS SQUIBB CO30 citations92
US7223757B2May 29, 2007
Tyrosine kinase inhibitors
BRISTOL MYERS SQUIBB CO16 citations91
US7232826B2Jun 19, 2007
Tyrosine kinase inhibitors
BRISTOL MYERS SQUIBB CO13 citations84
US7879855B2Feb 1, 2011
Pyrrolotriazine kinase inhibitors
BRISTOL MYERS SQUIBB CO10 citations83
US9556179B2Jan 31, 2017
Substituted imidazoles as casein kinase 1 D/E inhibitors
BRISTOL MYERS SQUIBB CO9 citations81
US11866430B2Jan 9, 2024
Naphthyridinone compounds useful as T cell activators
BRISTOL MYERS SQUIBB CO3 citations73
US7081454B2Jul 25, 2006
Tyrosine kinase inhibitors
BRISTOL MYERS SQUIBB CO6 citations72
US10669272B2Jun 2, 2020
Substituted naphthyridinone compounds useful as T cell activators
BRISTOL MYERS SQUIBB CO4 citations70
US7189716B2Mar 13, 2007
Tyrosine kinase inhibitors
BRISTOL MYERS SQUIBB CO4 citations62
US11713316B2Aug 1, 2023
Substituted naphthyridinone compounds useful as T cell activators
BRISTOL MYERS SQUIBB CO0 citations59
US10954238B1Mar 23, 2021
Substituted naphthyridinone compounds useful as T cell activators
BRISTOL MYERS SQUIBB CO0 citations59
US12492172B2Dec 9, 2025
Substituted quinazolinyl compounds useful as T cell activators
BRISTOL MYERS SQUIBB CO0 citations51
US12454531B2Oct 28, 2025
Substituted piperazine derivatives useful as T cell activators
BRISTOL MYERS SQUIBB CO0 citations51
US9242967B2Jan 26, 2016
Substituted bicyclic heteroaryl compounds
BRISTOL MYERS SQUIBB CO0 citations51
US7470696B2Dec 30, 2008
Tyrosine kinase inhibitors
BRISTOL MYERS SQUIBB CO1 citations51
US11964973B2Apr 23, 2024
Substituted bicyclic compounds useful as T cell activators
BRISTOL MYERS SQUIBB CO0 citations50
US9475817B2Oct 25, 2016
Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
BRISTOL MYERS SQUIBB CO1 citations50
US10961239B2Mar 30, 2021
TGF beta receptor antagonists
BRISTOL MYERS SQUIBB CO0 citations49
US11584747B2Feb 21, 2023
Substituted pyridopyrimidinonyl compounds useful as T cell activators
BRISTOL MYERS SQUIBB CO0 citations48
US9598423B2Mar 21, 2017
Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors
BRISTOL MYERS SQUIBB CO0 citations45
US9273058B2Mar 1, 2016
Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors
BRISTOL MYERS SQUIBB CO1 citations45
US9956220B2May 1, 2018
Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
BRISTOL MYERS SQUIBB CO0 citations34
VELAPARTHI UPENDER
5 patentsUS9145419B2Sep 29, 2015
Imidazopyridazinyl compounds
VELAPARTHI UPENDER3 citations61
US8212031B2Jul 3, 2012
Pyrrolotriazine kinase inhibitors
VELAPARTHI UPENDER1 citations51
US8148522B2Apr 3, 2012
Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate
VELAPARTHI UPENDER0 citations50
US8415340B2Apr 9, 2013
Triazine kinase inhibitors
VELAPARTHI UPENDER0 citations40
US8673922B2Mar 18, 2014
Azaindazole compounds
VELAPARTHI UPENDER0 citations38
RIGEL PHARMACEUTICALS INC
4 patentsUS9884868B2Feb 6, 2018
TGF-beta inhibitors
RIGEL PHARMACEUTICALS INC2 citations71
US11352360B2Jun 7, 2022
TGF-beta inhibitors
RIGEL PHARMACEUTICALS INC0 citations60
US10287295B2May 14, 2019
TGF-β inhibitors
RIGEL PHARMACEUTICALS INC0 citations51
US9981944B2May 29, 2018
GDF-8 inhibitors
RIGEL PHARMACEUTICALS INC0 citations41